JOHNSON & JOHNSON (JNJ)
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
📈 **POSITIVE** • High confidence analysis (84%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business